RxDoctor Payments Data

Kristie Burt, NP

Family · Leesburg, ALNPI 1073887659

Payments from drug & device makers

$6,064in general payments, 2019–2025

Across 363 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$672
  • AstraZeneca$663
  • Amarin Pharma, Inc.$484
  • Lilly USA, LLC$311
  • Amgen$309
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$5,89597%
  • Education$1693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,064 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$28,430
Medicare patients
121
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$94,957
OzempicSemaglutide78$85,130
EliquisApixaban87$79,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$43,950
TrulicityDulaglutide40$43,658
Tresiba Flextouch U-100Insulin Degludec47$38,622
JardianceEmpagliflozin50$37,450
FarxigaDapagliflozin Propanediol44$36,283
JanuviaSitagliptin Phosphate37$25,606
Tresiba Flextouch U-200Insulin Degludec17$18,224
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$17,759
KerendiaFinerenone24$16,434
XareltoRivaroxaban18$14,379
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$13,834
VascepaIcosapent Ethyl18$12,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$311$138,614122 claims
Novo NordiskOzempic$154$85,13078 claims
PfizerEliquis$238$79,99087 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$663$60,28491 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$672$50,47589 claims
Boehringer IngelheimJardiance$103$37,45050 claims
MerckJanuvia, Janumet Xr$75$29,15549 claims
BayerKerendia$92$16,43424 claims
Johnson & JohnsonXarelto$60$14,37918 claims
AbbVieLinzess$1,099$9,56312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.

Other family in Leesburg

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →